Clinical trials: GLP - 1
Glucagon Like Peptide-1 (GLP-1, Delayed Gastric Emptying
GLP_1 RA Ultrasound Study
The purpose of the study is to determine whether patients taking GLP-1 RAs have increased residual (left behind), gastric (stomach), contents due to delayed gastric emptying when following standard preoperative fasting guidelines.
- Conditions
- Glucagon Like Peptide-1 (GLP-1, Delayed Gastric Emptying, Risk of Aspiration, Diabetes
- Trial name
- NCT06581120
- Testing
- Glucagon-Like Peptide-1 receptor agonists, Point of Care Gastric Ultrasound
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Type 2 Diabetes, Blod Pressure
Vasodilatory and Metabolic Effects of Glucagon-like Peptide-1 in Periphery Circulation in Patients With and Without Type 2 Diabetes Mellitus
Diabetes and high blood pressure are risk factors for developing heart disease. An increase in the number of diabetes patients is expected.
- Conditions
- Type 2 Diabetes, Blod Pressure, Glucagon-like Peptide-1, Human Physiology
- Trial name
- NCT01689051
- Testing
- human glucagon-like peptide 1 (7-36)amide, human glucagon-like peptide 1 (9-36)amide
- Where
- Denmark
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Gastric Emptying, Glucagon-Like Peptide-1 Receptor Agonists
Effect of Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) on Gastric Emptying
This study aims to assess the effect of using Glucagon-like peptide-1 receptor agonists (GLP-1) receptor agonists on gastric emptying on surgical patients and whether specific guidelines need to be established for these patients.
- Conditions
- Gastric Emptying, Glucagon-Like Peptide-1 Receptor Agonists, Intermittent Fasting, Intraoperative Complication Due to Anesthesia
- Trial name
- NCT07140289
- Testing
- Ultrasound of gastric contents
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Wael Saasouh, MD
Type 2 Diabetes Mellitus
A Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZYD1, Following Subcutaneous Administration in Healthy Volunteers
ZYD1 is a novel GLP-1 receptor agonist. The ZYD1 exhibits increased stability to proteolytic cleavage, especially against dipeptidyl peptidase-4 (DPP-IV). ZYD1 is a potent antidiabetic agent without gastrointestinal side-effects.
- Trial name
- ZYD1 (NCT01972893)
- Testing
- ZYD1
- Where
- India
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Zydus Lifesciences Limited
Alcohol Dependence, in Remission, Addiction, Alcohol
Does Treatment With GLP-1 Reduce Alcohol Intake in Patients With Alcohol Dependence?
The study is a double-blinded, randomized, placebo-controlled, 26-weeks clinical trial. The objective of the trial is to investigate the effects of the GLP-1 receptor agonist Bydureon® (exenatide) vs.
- Trial name
- EXALT (NCT03232112)
- Testing
- Exenatide 2 MG Injection, BD PosiFlush (saline)
- Where
- Denmark
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Anders Fink-Jensen, MD, DMSci
Obesity, Overweight
A Study to Investigate the Effect of a Low-fat Meal and Evening Dosing on KAI-7535 in Participants Living With Obesity or Overweight
The primary objective of this study is to evaluate the effect of a meal and evening dosing on the pharmacokinetics (PK) of KAI 7535 in healthy participants living with obesity or overweight.
- Trial name
- NCT07294898
- Testing
- KAI-7535
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Kailera
Type 2 Diabetes Mellitus
Endothelial and Metabolic Effects of Glucagon-like Peptide-1 (GLP-1) in Coronary Circulation in Patients With Type 2 Diabetes Mellitus
GLP-1 is an incretin hormone which is discharged from the intestines after food intake. The hormone is known for its powerful insulinotropic and trophic effects on the beta cells in the pancreas and is currently used as an…
- Trial name
- NCT00923962
- Testing
- Glucagon like peptide-1, Adenosine
- Where
- Denmark
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Endocrine System Diseases
Gastric and Intestinal Satiation in Obese and Normal Weight Healthy People
The purpose of this study is to determine the reciprocal control between gastric functions and intestinal parameters in the development of satiation in obese people.
- Trial name
- NCT01456572
- Testing
- ensure plus, standardized test meal
- Where
- Switzerland
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Blood Sugar; High, Overweight and Obesity
Effect of a Glucagon Like Peptide 1 (GLP1) Booster in Healthy Humans
BACKGROUND GLP1 booster (GB) was designed to stimulate the endogenous production of GLP1, which in turn releases insulin, controls blood glucose level, suppresses appetite and thus helps people lose weight.
- Conditions
- Blood Sugar; High, Overweight and Obesity, Fat Burn, Obesity
- Trial name
- NCT06333496
- Testing
- GLP-1 Booster (GB)
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Alpine Biotech LLC
Appetite and General Nutritional Disorders
Intestinal Glucagon-like Peptide-1 (GLP-1) and the Physiological Role in Eating in Humans
The aim is to further establish a physiological role for GLP-1 as an endogenous satiety signal by examining the effect of the specific GLP-1 receptor antagonist exendin (9-39) on appetite and food intake in healthy male subjects.
- Trial name
- NCT01900340
- Testing
- Saline, Exendin 9-39, Exendin(9-39) plus ID nutrient
- Where
- Switzerland
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Sexual Desire
Effects of Glucagon-like-Peptide-1 Analogues on Sexuality
This study is to investigate the effects of GLP-1 analogues (combined with lifestyle interventions in comparison to lifestyle interventions only) on sexual desire, mood, quality of life, the reproductive axis, retinal vessel…
- Trial name
- Desire PLUS (NCT05598008)
- Where
- Switzerland
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Diabetes Mellitus Type 2
The Effect of Acipimox on GLP (Glucagon-like Peptide)-1 Secretion
Glucagon like peptide 1 is produced in enteroendocrine L cells in the small intestine stimulated by peroral food intake. GLP-1 induces insulin secretion, and analogues are used in the treatment of DM2 (type 2 diabetes mellitus).
- Trial name
- NCT02796950
- Testing
- Acipimox
- Where
- Denmark
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Gestational Diabetes Mellitus, Type 2 Diabetes Mellitus
Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)
A diagnosis of gestational diabetes mellitus (GDM)has significant implications for the future health of the mother. GDM is often the culmination of years of unrecognized and unmodified diabetes risk factors that lead to overt and…
- Conditions
- Gestational Diabetes Mellitus, Type 2 Diabetes Mellitus, Metabolic Syndrome, Impaired Glucose Tolerance
- Trial name
- NCT01234649
- Testing
- Metformin XR plus liraglutide
- Where
- United States
- Volunteers
- 153 people, healthy volunteers welcome
- Sponsor
- Woman's
Obesity
High Quality Protein for Assisting With Weight Loss
The purpose of this study is to determine if, in presence of a reduced calorie diet, a breakfast containing high quality protein source (eggs) would be more effective in reducing hunger and increasing feeling of fullness compared…
- Trial name
- Egg_breakfast (NCT03085511)
- Testing
- Egg breakfast (EB), Weight Loss Counseling, Weight Loss Diet
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Texas Tech University
PYY, Ghrelin
The Comparison of PYY, Ghrelin, GLP1, Glucose Level, Level of Satiety, and Ad Libitum Intake in Obese and Non-Obese Patients After Breakfast With Balanced Macronutrient Composition
Obesity can occur due to an imbalance of energy. This energy balance is greatly influenced by hunger and satiety. Obese person cannot resist hunger, while non obese can control hunger.
- Conditions
- PYY, Ghrelin, Appetite, Gut Hormones
- Trial name
- NCT03701503
- Testing
- Diet with balance composition to know the effect of a meal to gut hormones in obese and non obese women
- Where
- Indonesia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Universitas Indonesia
Type 2 Diabetes Mellitus, PreDiabetes
Glucagon-like Peptide-1 Levels, Insulin Resistance and Insulin Sensitivity Index in Type 2 Diabetes Mellitus
This study is conducted to examine GLP-1, insulin resistance and insulin sensitivity portfolio in Malay, Chinese and Indian populations in Malaysia and to study the effect of DPPIV inhibitor in T2DM patients with different…
- Trial name
- GLP-1 (NCT03659461)
- Testing
- Sitagliptin
- Where
- Malaysia
- Volunteers
- 174 people, healthy volunteers welcome
- Sponsor
- National University of Malaysia
GLP-1, Obesity &Amp; Overweight
Effect of a Dietary Supplement on Hormones Involved in Appetite Regulation in Overweight and Obese Adults
Obesity is a chronic condition linked to numerous health risks and affects more than one billion people worldwide. While pharmacological treatments such as incretin-based therapies are available, they may have side effects, are…
- Conditions
- GLP-1, Obesity &Amp; Overweight, Dietary Supplement
- Trial name
- NCT07240246
- Testing
- Intervention: Dietary Supplement with Plant Extracts
- Where
- Austria
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- FFoQSI - Austrian Competence Centre for Feed and Food Quality, Safety & Innovation
Hyperglycemia
Exendin(9-39)Amide as a Glucagon-like Peptide-1 (GLP-1) Receptor Antagonist in Humans
The purpose of this study is to determine the dose of the GLP-1 receptor antagonist exendin(9-39) which blocks the insulinotropic action of synthetic GLP-1 by at least 95%.
- Trial name
- NCT00393445
- Testing
- GLP-1 control, GLP-1 and Exendin(9-39) 300, saline control
- Where
- Germany
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Ludwig-Maximilians - University of Munich
Endocrine System Diseases
Oral Glucose Stimulation in Normal-weight and Obese Volunteers
The objective of this study is to examine gastric emptying and satiety hormones after oral glucose stimulation in 2 different concentrations in normal-weight and obese patients.
- Trial name
- NCT01875575
- Testing
- Glucose 25g, Glucose 10g
- Where
- Switzerland
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Type 2 Diabetes
SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies
The aim of this study is to detail the (mechanisms underlying the) actions of the GLP-1 receptor agonists and DPP-4 inhibitors on the cardiovascular, renal and gastrointestinal systems in patients with Type 2 Diabetes Mellitus.
- Trial name
- NCT01744236
- Testing
- Liraglutide, Sitagliptin, Exenatide
- Where
- Netherlands
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Amsterdam UMC, location VUmc